News | October 07, 2022
Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
There is also a growing interest in whole generation sequencing (WGS)
Subscribe To Our Newsletter & Stay Updated
